Anemia

Correcting Anemia Reduces Odds of Renal Transplant Failure

December 29, 2011

Complete correction of anemia (hemoglobin, 13 g/dL or higher) in kidney transplant recipients slows progression to chronic allograft nephropathy, a study found.
 

FDA Committee Favors Peginesatide

December 15, 2011

The FDA's Oncologic Drugs Advisory Committee, in a 15 to 1 vote, has agreed that peginesatide demonstrates a favorable benefit/risk profile for use in treatment of dialysis patients with anemia resulting from chronic kidney disease (CKD).
 

Novel Therapy for CKD Anemia Advances

November 16, 2011

PHILADELPHIA—A novel treatment for chronic kidney disease (CKD) patients with anemia is showing positive results following a Phase 1/2 clinical trial, according to findings reported at Kidney Week 2011.
 

IV Iron Drug Shows Advantages in Head-to-Head Trial

November 12, 2011

PHILADELPHIA—Ferumoxytol has an efficacy comparable to iron sucrose in treating iron deficiency anemia in patients with chronic kidney disease (CKD), but is associated with lower adverse event (AE) rates, according to the findings a head-to-head comparison of the two formulations presented at Kidney Week 2011.
 

Once-Monthly ESA Maintains Stable Hemoglobin Levels

November 12, 2011

PHILADELPHIA—Once-monthly peginesatide, an investigational peptide-based erythropoiesis stimulating agent (ESA), is similar to epoetin administrated one to three times weekly in maintaining mean hemoglobin levels in the 10-12 g/dL range in hemodialysis patients with anemia, according to study findings presented at Kidney Week 2011.
 

EPO Use Declining After Bundling Introduced

November 12, 2011

PHILADELPHIA—Epoetin alfa (EPO) use has decreased and intravenous (IV) iron use has increased significantly in private dialysis units since the introduction of the Medicare bundling rule for end-stage renal disease services, data presented at Kidney Week 2011 suggest.
 

IV Iron Use for Anemia Rising, ESA Use Falling

November 11, 2011

PHILADELPHIA—The use of intravenous (IV) iron for managing anemia in hemodialysis (HD) patients has increased steadily from 2002 to 2008, even after declines in the use of erythropoiesis stimulating agents (ESAs), as reported from data presented at Kidney Week 2011.
 

HD-Related Damage Not a Factor in CKD-Related Anemia

November 11, 2011

PHILADELPHIA—Mechanical damage to red blood cells (RBC) from hemodialysis (HD) does not contribute to anemia in HD patients, according to study findings presented at Kidney Week 2011.
 

Response to ESAs Predicts ESRD Risk

November 11, 2011

PHILADELPHIA—Patients with chronic kidney disease (CKD) who have a low response to erythropoiesis-stimulating agents (ESAs) are at increased risk of progressing to end-stage renal disease (ESRD), investigators reported at Kidney Week 2011.
 

ESA Resistance Increases Death Risk More in HD than PD Patients

November 10, 2011

PHILADELPHIA—Most patients on peritoneal dialysis (PD) receive substantially lower doses of erythropoiesis stimulating agents (ESAs) for the same achieved hemoglobin levels compared with patients on hemodialysis (HD), investigators reported at Kidney Week 2011.
 

BP Rises with ESAs Not Relate to Vasoconstriction

November 10, 2011

PHILADELPHIA—New study findings may narrow down the possible causes of increased blood pressure (BP) result from the use of erythropoiesis stimulating agents (ESAs) to correct renal anemia, according to a report presented at Kidney Week 2011.
 

Diabetes Boosts CKD Patients' Comorbidities

November 10, 2011

PHILADELPHIA—Patients with chronic kidney disease (CKD) who also have diabetes have significantly higher rates of anemia, cardiovascular disease, and other comorbidities compared with nondiabetic CKD patients, study findings presented at Kidney Week 2011 show.
 

Poor Response to ESAs Increases Death Risk in Hemodialysis Patients

September 07, 2011

Mortality in hemodialysis (HD) patients can be influenced by their responsiveness to erythropoiesis-stimulating agents (ESAs), according to Japanese researchers.
 

FDA Agrees to Review NDA for Peginesatide

July 27, 2011

The FDA has agreed to review a New Drug Application (NDA) for peginesatide for the treatment of anemia associated with chronic kidney disease (CKD) in adult dialysis patients, according to a joint announcement by the two companies colloraborating on the development of the drug.
 

FDA Recommend More Conservative Dosing of ESAs

July 13, 2011

The FDA is calling for more conservative dosing of erythropoiesis-stimulating agents (ESAs) when used to treat anemia in CKD patients due to the increased risks of cardiovascular events such as stroke, thrombosis, and death.
 
Your Practice

Our exclusive coverage of Kidney Week 2011 in Philadelphia includes interviews, videos and noteworthy clinical reports.

Sections: Anemia | Transplantation
Secondary Hyperparathyroidism | General News
More: Videos

Latest CME Article

Renal & Urology News includes a CME article in every print issue, which will also be available online.

View the latest installment:

Renal Cell Carcinoma Tumor

An Update on Robotic-Assisted Partial Nephrectomy

Renal Nutrition Update


Renal Nutrition Update

Research has shown that individuals who exercise have lower risk for chronic diseases than individuals who do not exercise.

Your Practice


Since its inception, health care providers have struggled with the need to protect patient privacy, share information, and keep paper work under control.

Read more on
Complying with HIPAA

Have any practice management topics that you'd like us to cover?
Let us know.
Popular Topics
Acute Kidney Injury Anemia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease CKD Diabetes Epidemiology Erectile Dysfunction Hemodialysis Hyperphosphatemia Hypertension Infection Kidney Cancer Kidney Stones Nutrition Overactive Bladder Peritoneal Dialysis Prostate Cancer PSA Reproductive Medicine Transplantation Urinary Incontinence UTI

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions